Last reviewed · How we verify
NCT04351295
Efficacy of Faviprevir in COVID-19 Treatment
Completed
Phase 2, PHASE3
Last updated 1 November 2021
What this trial tests
Phase 2, PHASE3 trial testing Favipiravir in COVID in 92 participants. Completed in 28 September 2020.
Timeline
20 April 2020
Primary endpoint
28 September 2020
28 September 2020
28 September 2020
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 20 April 2020 |
| Primary completion | 28 September 2020 |
| Estimated completion | 28 September 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Favipiravir (FAVIPIRAVIR) — full drug profile →
- Chloroquine (CHLOROQUINE) — full drug profile →
Conditions studied
- COVID — all drugs for COVID →
Sponsor
Tanta University
Who can join
Adults 18 to 80, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Faviprevir in COVID-19 treatment
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of favipiravir in the treatment of COVID-19.
Joshi S, Parkar J, Ansari A, Vora A, et al · · 2021 · cited 244× · PMID 33130203 · DOI 10.1016/j.ijid.2020.10.069 -
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206 -
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794 -
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
Muralidar S, Ambi SV, Sekaran S, Krishnan UM. · · 2020 · cited 184× · PMID 32971147 · DOI 10.1016/j.biochi.2020.09.018 -
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, et al · · 2020 · cited 93× · PMID 32468014 · DOI 10.3892/ijmm.2020.4608 -
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, et al · · 2021 · cited 85× · PMID 33492523 · DOI 10.1007/s00705-021-04956-9 -
COVID-19: Progress in diagnostics, therapy and vaccination.
Liu X, Liu C, Liu G, Luo W, et al · · 2020 · cited 85× · PMID 32685022 · DOI 10.7150/thno.47987 -
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
Verify or expand the search:
- PubMed search for NCT04351295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Favipiravir
Trials testing the same drug.
- NCT06860334 — UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF · Phase 2 · not yet recruiting
- NCT06488300 — Assessing Antiviral Treatments in Early Symptomatic RSV · Phase 2 · recruiting
- NCT05940545 — UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF · Phase 1, PHASE2 · unknown
- NCT05648448 — A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza · Phase 2 · recruiting
- NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04351295 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 1 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing